Anyone have info on this new contract with Thrombogenetics? Pay range, how large are the territories, info on Thromogenetics/how are they to work for, etc?
Thank You
Thank You
New retina contract 6513
- Thread starter Anonymous
- Start date
-
- Tags
- None
My apology, I thought it was new. There were two postings in my area, usually two openings at once leads me to believe it is new. I did submit my resume today. If anyone has insight about this contract and is willing to share the info, it would be appreciated.
Thank you!
Thank you!
Big geography. Fly to parts of territory. Great company. Where are the open spots?
and thank you for the feedback!THIS COMPANY IS GOING NOWHERE FAST !
ThromboGenics Plunges on Jetrea Sales Forecast: Brussels Mover
By Simeon Bennett - Aug 30, 2013 4:16 AM ET
ThromboGenics NV (THR), the Belgian eye-drug developer, fell as much as 30 percent after forecasting that sales of its only approved product won’t increase in the second half of the year, missing analysts’ estimates.
ThromboGenics dropped to as low as 19.71 euros, the steepest intraday decline since it sold shares to the public in 2006. The number of shares that exchanged hands was more than five times the three-month daily average.
Second-half sales of Jetrea, the drug approved in the U.S. last year to treat vitreomacular adhesion, will be at the same level as first-half sales of 12.5 million euros ($17 million), Heverlee-based ThromboGenics said after the close of trading yesterday. That implies full-year sales will be 36 percent less than the analyst consensus of 39.4 million euros, according to Richard Vosser, an analyst at JPMorgan Chase & Co. in London.
The hurdles to introducing Jetrea in the U.S. were “higher than we had expected,” Vosser wrote in a note. He cut his December 2014 price target for the stock to 24 euros from 34 euros.
The shares traded 20 percent lower at 22.53 euros as of 10:11 a.m. in Brussels. The stock has dropped 47 percent this year, compared with a 13 percent gain in Belgium’s benchmark Bel20 Index.
ThromboGenics Plunges on Jetrea Sales Forecast: Brussels Mover
By Simeon Bennett - Aug 30, 2013 4:16 AM ET
ThromboGenics NV (THR), the Belgian eye-drug developer, fell as much as 30 percent after forecasting that sales of its only approved product won’t increase in the second half of the year, missing analysts’ estimates.
ThromboGenics dropped to as low as 19.71 euros, the steepest intraday decline since it sold shares to the public in 2006. The number of shares that exchanged hands was more than five times the three-month daily average.
Second-half sales of Jetrea, the drug approved in the U.S. last year to treat vitreomacular adhesion, will be at the same level as first-half sales of 12.5 million euros ($17 million), Heverlee-based ThromboGenics said after the close of trading yesterday. That implies full-year sales will be 36 percent less than the analyst consensus of 39.4 million euros, according to Richard Vosser, an analyst at JPMorgan Chase & Co. in London.
The hurdles to introducing Jetrea in the U.S. were “higher than we had expected,” Vosser wrote in a note. He cut his December 2014 price target for the stock to 24 euros from 34 euros.
The shares traded 20 percent lower at 22.53 euros as of 10:11 a.m. in Brussels. The stock has dropped 47 percent this year, compared with a 13 percent gain in Belgium’s benchmark Bel20 Index.
MORE INFO
Aug 30 (Reuters) - Belgium-based biomedical group ThromboGenics lost nearly a third of its stock market value after it said the second half would be similar to the first as it works to win over doctors to its flagship drug.
Shares in ThromboGenics, maker of newly launched eye drug Jetrea, slumped on Friday to their lowest level since July last year after the company warned second-half sales would not be significantly higher than the first.
"We expect similar numbers in the second half as we have seen in the first half," Patrik De Haes, the company's CEO, said after the company posted results late on Thursday.
De Haes said the drug would take time to take off because it was a new method of treating vitreomacular adhesion, an ageing-related vision problem that can lead to blindness, received EU approval in March.
The drug's performance is tied to the fact that it does not yet have a U.S. J-code, which would grant physicians automatic reimbursement, making them more likely to prescribe the drug.
While the company expects the drug will receive the J-code in 2014, the CEO said this would change the outlook immediately.
"Don't expect in January a hockey stick but let's say ... the financial risk that the doctor was incurring so far will be gone," De Haes said.
Take-up in the United States is just 6 percent of the eligible 50,000 patients, brokerage Jefferies said in a note to clients.
In Europe, pending recommendations from German and British drug approval bodies to use Jetrea on moderate to severe patients would help the drug's roll-out.
ThromboGenics shares fell by as much as 30 percent to a low of 19.71 euros, before recovering slightly to be down 22 percent at 0847 GMT.
Analysts at Jefferies said: "We likely underestimated the physician education required at launch and potentially have too high peak penetration in milder patients." (Reporting by
Aug 30 (Reuters) - Belgium-based biomedical group ThromboGenics lost nearly a third of its stock market value after it said the second half would be similar to the first as it works to win over doctors to its flagship drug.
Shares in ThromboGenics, maker of newly launched eye drug Jetrea, slumped on Friday to their lowest level since July last year after the company warned second-half sales would not be significantly higher than the first.
"We expect similar numbers in the second half as we have seen in the first half," Patrik De Haes, the company's CEO, said after the company posted results late on Thursday.
De Haes said the drug would take time to take off because it was a new method of treating vitreomacular adhesion, an ageing-related vision problem that can lead to blindness, received EU approval in March.
The drug's performance is tied to the fact that it does not yet have a U.S. J-code, which would grant physicians automatic reimbursement, making them more likely to prescribe the drug.
While the company expects the drug will receive the J-code in 2014, the CEO said this would change the outlook immediately.
"Don't expect in January a hockey stick but let's say ... the financial risk that the doctor was incurring so far will be gone," De Haes said.
Take-up in the United States is just 6 percent of the eligible 50,000 patients, brokerage Jefferies said in a note to clients.
In Europe, pending recommendations from German and British drug approval bodies to use Jetrea on moderate to severe patients would help the drug's roll-out.
ThromboGenics shares fell by as much as 30 percent to a low of 19.71 euros, before recovering slightly to be down 22 percent at 0847 GMT.
Analysts at Jefferies said: "We likely underestimated the physician education required at launch and potentially have too high peak penetration in milder patients." (Reporting by
you need somebody to buy it before it get reimbursed!